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Purpose
This phase II clinical trial was conducted to evaluate the activity and safety of a combination
treatment of paclitaxel (Genexol
�) plus carboplatin in patients with advanced non-small cell
lung cancer. 
Materials and Methods
Chemotherapy-naïve patients having histologically confirmed advanced or metastatic non-
small cell lung cancer were enrolled. Genexol
� was administered at 225 mg/m
2 intravenous
(IV) infusion over 3 hours, followed by carboplatin (area under the concentration-time
curve=6) IV on day 1 every 3 weeks. 
Results
Twenty-eight patients were enrolled between January 2003 and January 2005. A total of 110
cycles of chemotherapy were given. The median number of chemotherapy cycles was 4. A
total of 25 study patients were evaluable. On an intent-to-treat basis, there were ten partial
responses (response rate 35.7%). The median time-to-progression was 3.2 months (95%
confidence interval [CI], 1.5 to 4.9) and the median overall survival was 8.2 months (95% CI,
4.1 to 12.3). The main hematologic grade 3/4 toxicity was neutropenia, which was observed
in 14 (50.0%) patients. The main non-hematologic toxicity was peripheral neuropathy, which
was observed in 12 patients (42.9%). Grade 3/4 neuropathy occurred in 8 patients (28.6%)
and three patients discontinued treatment because of neuropathy. 
Conclusion
In this trial, the combination of Genexol
� and carboplatin showed significant activity as first
line treatment for patients with advanced or metastatic non-small cell lung cancer. However,
a modest dose reduction of Genexol
�is needed due to sensory neuropathy. 
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Lung cancer is the fourth most common cancer and the leading
cause of cancer deaths in Korea [1].The platinum-based regimen using
paclitaxel, gemcitabine and docetaxel has shown high response rates
and a survival benefit for patients with advanced non-small cell lung
cancer (NSCLC). No significant difference in survival was observed
among four commonly used regimens, but the combination regimen of
paclitaxel and carboplatin had a lower rate of toxic effects than the
other regimens [2,3]. When considering toxicity profile, a combination
chemotherapy of paclitaxel and carboplatin is an appropriate option in
advanced or metastatic NSCLC. Previously, paclitaxel (Taxol
�,
Bristol-Myers Squibb Co., Princeton, NJ) was obtained using a semi-
synthetic process from Taxus baccata, but another paclitaxel, Genexol
�
(Samyang Genex Co., Seoul, Korea) was produced from Taxus
chinensis using plant cell culture technology. This technology enables
the manufacture of Genexol
� with a high purity, low purification cost,
constant yield, and without environmental problems. In a phase II trial
with advanced NSCLC patients, combination chemotherapy using
Genexol
� and cisplatin showed no less response than a previous study
and had no significant toxicity [4]. We conducted a phase II trial to
evaluate the safety and efficacy of a combination treatment of another
paclitaxel (Genexol
�) plus carboplatin in patients with advanced
NSCLC. 
Materials and Methods
1 Eligibility criteria
The eligibility criteria were as follows: 1) histologically-confirmed
inoperable, locally advanced or metastatic NSCLC, 2) patients
between 18 and 75 years of age, 3) no previous chemotherapy, 4) an
Eastern Cooperative Oncology Group (ECOG) performance status of
0-2, 5) no serious or uncontrolled concurrent medical illness, 6) at least
one radiographically measurable lesion, and 7) adequate baseline he-
matologic function, defined as (an absolute neutrophil count [ANC] ≥
1.5×10
9/L, and a platelet count ≥100×10
9/L), adequate hepatic
function (serum bilirubin ≤1.25×upper normal limit [UNL], serum
aspartate aminotransferase alanine aminotransferase ≤2.5×UNL and
serum alkaline phosphatase ≤5.0×UNL), and adequate renal
function (serum creatinine ≤1.5 mg/dL). 8) All patients gave their
written informed consent to participate in the study, which was
approved by the local institutional review boards. The exclusion criteria
included the following: 1) pre-existing peripheral neuropathy, 2)
concurrent or prior malignancy, except curatively resected cervical car-
cinoma in situ or squamous cell carcinoma of the skin, 3) active in-
fection, 4) brain metastasis, 5) pregnancy confirmed, and 6) concurrent
treatments that interfered with the study’s evaluation. 
2   Treatment protocol and dose modifications
1) Chemotherapy protocol
Genexol
� was supplied by Samyang Genex Co. as a concentrated
sterile solution for intravenous (IV) administration in a 5 mL vial
containing 30 mg of paclitaxel in polyoxyethylated castor oil and
dehydrated alcohol (Cremophor EL/ethanol). The patients received
Genexol
�, 225 mg/m
2 as a 3-hour IV infusion followed by carboplatin,
area under the concentration-time curve (AUC)=6, as a 1-hour IV
infusion on day 1 every 3 weeks. The Genexol
� was given with
premedication as follows: dexamethasone 10 mg (or its equivalent) IV
administered 12 hours and 30 minutes before the Genexol
�,
chlorpheniramine maleate 4 mg (or its equivalent) IV, ranitidine 50 mg
(or its equivalent) IV, 30 minutes before the Genexol
�. Antiemetic
prophylaxis was given according to a local protocol. In the absence of
progressive disease or intolerable toxicity, the patients were treated for
a maximum of six cycles. Patients who achieved a complete or partial
response (PR) could receive two additional cycles of chemotherapy
after best response, to a maximum 8 cycles. Granulocyte colony-sti-
mulating factor was not routinely used in the study. 
2) Treatment delays and dose modifications
Each cycle was started if the ANC and platelet counts on the day of
treatment were ≥1.5×10
9/L and ≥100×10
9/L, respectively. In the
case of any grade 3 or greater toxicity, except alopecia, chemotherapy
was delayed 1 week, then restarted after recovery. The patients were
treated at three dose levels (0, -1, -2) as follows: enrolled patients were
started at dose level 0, in which they received Genexol
�, 225 mg/m
2,
plus carboplatin, AUC=6. If grade 3/4 thrombocytopenia or febrile
neutropenia, grade 4 neutropenia, or grade 3/4 non-hematologic
toxicity were observed in the previous cycle, the dose of test drugs was
decreased to level -1 (Genexol
�, 180 mg/m
2, plus carboplatin,
AUC=5). If the above toxicities occurred after dose reduction, the dose
of drugs was decreased to level -2 (Genexol
�, 135 mg/m
2, plus
carboplatin, AUC=4). If a recovery was still not achieved by day 35 of
treatment, the patient was withdrawn from the study. 
3 Response and toxicity assessment
A pretreatment evaluation was performed within 2 weeks of the
therapy initiation, including full history, physical examination, com-
plete blood cell counts (CBC) with the differential count, serum
biochemistry, chest X-ray, chest computed tomography (CT), Brain
CT and site-specific imaging. The response to treatment was assessed
according to the response evaluation criteria in solid tumors (RECIST)
criteria. All the patients who received at least one cycle of chemothe-
rapy were considered evaluable for toxicity. CT scans of the measu-
rable lesions were performed within 2 weeks prior to treatment. After
every 2 cycles of chemotherapy, CT scans were performed to deter-
mine the response of the disease, or sooner if there was evidence of any
clinical deterioration. CBC with the differential count and serum
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cycle, and the toxicity was graded according to the National Cancer
Institute common toxicity criteria (NCI-CTC version 2.0). 
4 Statistical analysis
The trial was conducted according to the group sequential design
with the response rate as the primary efficacy endpoint. The number of
patients required for the study was calculated based on a targeted re-
sponse rate of 45% and a minimum response rate of 25%, with α error
of 0.1 and βerror of 0.2. Analysis of the clinical efficacy was per-
formed according to an intent-to-treat analysis. All patients who re-
ceived at least two cycles of treatment, or progressed after one course
of chemotherapy, were assessable for response and patients who re-
ceived at least one course were assessable for toxicity. The time to pro-
gression (TTP) was calculated from the 1st day of chemotherapy to the
date of disease progression or the last examination, and the overall
survival (OS) from the first day of chemotherapy to the date of death or
the last follow-up. The Kaplan-Meier method was used to analyze the
TTP and OS, and the 95% confidence interval (CI) for the median time
to event was computed. The actual delivered dose-intensity (DI) was
calculated as the ratio of the total dose (expressed in mg) per m
2 actu-
ally received by the patient, divided by the actual total treatment du-
ration expressed in weeks. The relative DI was calculated as the ratio of
the actual delivered DI to the DI planned by the protocol. The SPSS ver.
14.0 (SPSS Inc., Chicago, IL) were used for the statistical computation. 
Results
1 Patient characteristics
Between January 2003 and January 2005, 28 patients with a median
age of 63 years (range, 45 to 73 years) from Seoul, Bucheon, and
Cheonan Soonchunhyang University Hospital were studied. The
patient baseline characteristics are listed in Table 1. There were 20 men
and 8 women, and 10 patients (35.7%) had an ECOG performance
status of 2. Twenty patients (71.4%) had primary metastatic disease
and 8 patients (28.6%) had stage IIIb disease. The most common
histologic type of tumor was adenocarcinoma. 
2  Tumor responses and survival
Twenty-five of the enrolled 28 patients were evaluable for response
according to the RECIST criteria. Three patients were excluded from
the response analysis because these patients declined continuation of
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Table 1. Patient characteristics
No. of patients (%)
No. of enrolled patients 28
Median age (range, yr) 63 (45-73)
Gender
Male 20 (71.4)
Female 8 (28.6)
ECOG performance status
0-1 18 (64.3)
2 10 (35.7)
Stage
IIIB 8 (28.6)
IV 20 (71.4)
Pathology
Adenocarcinoma 17 (60.7)
Squamous cell carcinoma 10 (35.7)
Others 1 (3.6)
ECOG, Eastern Cooperative Oncology Group.
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Fig. 1. Kaplan-Meier curve for time-to-progression.
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Fig. 2.  Kaplan-Meier curve for overall survival.treatment for voluntary withdrawal after one cycle. Ten patients
(35.7%) achieved a PR, 7 patients (25.0%) had stable disease, and 8
patients (28.6%) progressed during the course of treatment. None of
the patients achieved a complete response. From intent-to-treat
analysis, the overall response rate was 35.7%. The median follow-up
duration was 8.1 months (range, 0.4 to 23.5 months). All patients were
dead. The TTP and OS were 3.2 months (95% CI, 1.5 to 4.9 months)
(Fig. 1) and 8.2 months (95% CI, 4.1 to 12.3 months) (Fig. 2),
respectively. 
3 Toxicity and dose intensity
One hundred ten chemotherapy cycles were administered to the 28
patients. The median number of cycles was 4 (range, 1 to 8). Table 2
summarizes the incidence of the main toxicities. The major grade 3-4
hematologic toxicity was neutropenia (50.0%). However, febrile
neutropenia was not encountered. The main non-hematologic toxicity
was peripheral neuropathy, which was observed in 12 patients
(42.9%). Grade 3/4 neuropathy occurred in 8 patients (28.6%), and
three patients (10.7%) discontinued the treatment because of peripheral
neuropathy. A dose reduction was required in 12 patients; eight
patients, due to peripheral neuropathy, and four patients, due to grade 4
neutropenia. A grade 3-4 hypersensitivity reaction to Genexol
�was not
observed. The relative dose intensities of Genexol
� and carboplatin
were 74.4% and 77.2% of planned doses, respectively. There were no
treatment-related deaths. 
Discussion
Platinum-based combination chemotherapy has shown a high
response rate and survival benefit for patients with advanced or
metastatic NSCLC, but none of the combination chemotherapy re-
gimens (paclitaxel+cisplatin vs. gemcitabine+cisplatin vs. do-
cetaxel+cisplatin vs. paclitaxel+carboplatin) have shown a significant
advantage over the others for the treatment of advanced NSCLC [2].
The major toxicities of paclitaxel are hypersensitivity, myalgia and
peripheral neuropathy. The use of carboplatin instead of cisplatin may
reduce the occurrence of peripheral neurotoxicity, and by using the
AUC, myelotoxicity can be manageable [5]. Based on this evidence,
we investigated the activity and safety of a combination treatment of
Genexol
� plus carboplatin in patients with advanced NSCLC.
Combination chemotherapy with Genexol
� plus cisplatin showed no
less response than the previous study, with no considerable toxicity [4].
However, the result of a Genexol
� plus carboplatin combination
regimen for treating NSCLC was not published. 
The results of this study showed that the regimen is an effective
combination chemotherapy as first-line treatment for advanced
NSCLC. The response rate, TTP and OS of this trial were 35.7%, 3.2
months and 8.2 months, respectively. These results were within the
range of previous trials, where platinum-based chemotherapy was used
for treatment of advanced NSCLC [2,3,6,7]. A severe hypersensitivity
reaction caused by paclitaxel has been reported to develop in 1 to 3%
of patients during a 3-hour infusion, however, we observed no patient
who experienced a grade 3/4 of hypersensitivity reaction in this trial
[2,8]. Myelotoxicity was not greater than in the previous report and no
toxic death was noticed. Neutropenia was the most frequent hema-
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Patient (n=28) Cycle (n=110)
Toxicity
Grade 1/2 (%) Grade 3/4 (%) Grade 1/2 (%) Grade 3/4 (%)
Hematologic
Neutropenia 6/28 (21.4) 14/28 (50.0) 31/110 (28.2) 23/110 (20.9)
Thrombocytopenia 3/28 (10.7) 3/28 (10.7) 11/110 (10.0) 6/110 (5.5)
Anemia 10/28 (35.7) 6/28 (21.4) 34/110 (30.9) 9/110 (8.2)
Hypersensitivity 4/28 (14.3) - 15/110 (13.6) -
Fatigue 6/28 (21.4) - 34/110 (30.9) -
Myalgia 9/28 (32.1) 4/28 (14.3) 26/110 (23.6) 10/110 (9.1)
Gastrointestinal
Nausea 8/28 (28.6) - 21/110 (19.1) -
Vomiting 6/28 (21.4) - 18/110 (16.4) -
Diarrhea 2/28 (7.1) - 8/110 (7.3) -
Constipation 3/28 (10.7) - 20/110 (18.2) -
Stomatitis 2/28 (7.1) - 5/110 (4.5) -
Neurosensory 4/28 (14.3) 8/28 (28.6) 18/110 (16.4) 21/110 (19.1)
Hepatic 
AST/ALT 5/28 (17.9) - 8/110 (7.3) -
Renal creatinine -- - -
Table 2. Toxicities according to National Cancer Institute common toxicity criteria 
AST, aspartate aminotransferase; ALT, alanine aminotransferase.Han Jo Kim, et al_Genexol
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tologic toxicity, although no febrile neutropenia was seen. Except for
neurotoxicity, non-hematologic problems were mild and manageable.
Neurotoxicity was the most serious problem. It was observed in 12
patients (42.9%), and grade 3/4 neuropathy occurred in 8 patients
(28.6%). Three patients (10.7%) discontinued the treatment because of
peripheral neuropathy, however, all these patients achieved a partial
response. A dose reduction was required in 8 patients due to peripheral
neuropathy, however, based on univariate analysis, grade 3/4 neu-
ropathy was not a significant factor affecting OS and response. Of the 8
patients who required dose reduction, 5 patients (62.5%) had an ECOG
performance status of 2. 
Neurotoxicity was more common in patients with poor performance
status in our study. Although we used carboplatin, instead of cisplatin
to reduce neurotoxicity, the rate of grade 3/4 neuropathy was relatively
high compared to other studies [2]. Perhaps the rate of toxicity reflected
the relatively high dose of Genexol
�. A higher dose of paclitaxel (225
mg/m
2 vs. 175 mg/m
2) combined with carboplatin (AUC=6) prolongs
the median time to progression but causes more neurotoxicity and neu-
tropenia [8-10]. However, to make such an assumption, more evidence
should be provided, i.e., 175 mg/m
2 vs. 225 mg/m
2 of Genexol
� in
caucasian and asian patients. 
Conclusion 
Although our study was not a randomized trial comparing paclitaxel
plus carboplatin combination chemotherapy, Genexol
�and carboplatin
is an effective regimen for patients with advanced or metastatic
NSCLC, and our results indicate that, when used with this schedule,
Genexol
�dose not appear to be safe from a neurotoxicity. Modest dose
reduction of Genexol
�is needed. 
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